Interestingly, anti-ERBB2 agents may induce the activation of NF-kB, enhancing the oncogene addiction of ERBB2-positive cells to NF-kB, implying that NF-kB initiation could represent a putative resistance mechanism to anti-ERBB2 agents in ERBB2-positive BC patients [56]. Here, NFKB1 is linked to breast cancer.